CASTOR status and evolution

In January 1999, CERN began to develop CASTOR ("CERN Advanced STORage manager"). This Hierarchical Storage Manager targetted at HEP applications has been in full production at CERN since May 2001. It now contains more than two Petabyte of data in roughly 9 million files. In 2002, 350 Terabytes of data were stored for COMPASS at 45 MB/s and a Data Challenge was run for ALICE in preparation for the LHC startup in 2007 and sustained a data transfer to tape of 300 MB/s for one week (180 TB). The major functionality improvements were the support for files larger than 2 GB (in collaboration with IN2P3) and the development of Grid interfaces to CASTOR: GridFTP and SRM ("Storage Resource Manager"). An ongoing effort is taking place to copy the existing data from obsolete media like 9940 A to better cost effective offerings. CASTOR has also been deployed at several HEP sites with little effort. In 2003, we plan to continue working on Grid interfaces and to improve performance not only for Central Data Recording but also for Data Analysis applications where thousands of processes possibly access the same hot data. This could imply the selection of another filesystem or the use of replication (hardware or software).Comment: Talk from the 2003 Computing in High Energy and Nuclear Physics (CHEP03), La Jolla, Ca, USA, March 2003, 2 pages, PDF. PSN TUDT00

Oxydation biocatalytique de liaison C-H non activée pour la synthèse de dérivés bêta-hydroxylamines (application à la synthèse d'acides aminés non protéinogènes)

Le travail présenté dans ce manuscrit porte sur la recherche de nouveaux membres de la famille des dioxygénases a-cétoglutarate et fer dépendantes (a-KAO) et leur application en synthèse organique. Dans un premier, ce travail a consisté à chercher de nouvelles enzymes selon une approche génomique basée sur l homologie de séquence et le partage d un motif InterPro. Deux criblages haut débit avec 79 et 127 enzymes candidates ont ensuite été effectués sur des panels constitués respectivement de 23 et 36 substrats, structurellement plus ou moins proches des substrats métaboliques. Huit nouvelles a-KAO ont ainsi pu être découvertes. Parmi ces huit nouvelles a-KAO, quatre ont été étudiées plus en détail. Après optimisation des conditions de réaction pour chaque enzyme, des montées en échelle ont été réalisées pour caractériser les produits formés. A partir de ces quatre enzymes, la (3S)-3-hydroxy-L-lysine, un dérivé cyclisé de la (4R)-4-hydroxy-L-lysine, (3S)-3-hydroxy-L-ornithine et un dérivé de la (3S)-3-hydroxy-L-arginine ont pu être produits. Nous avons proposé une synthèse biocatalytique de mono et dihydroxydiamines en couplant une ou deux a-KAO avec une décarboxylase. Les (2S)-1,5-diamino-2-pentanol, 1,5-diamino-3-pentanol, (2S)-1,4-diamino-2-butanol et (2S,3S)-1,5-diamino-2,3-pentanediol ont ainsi été obtenus avec de bonnes conversions.The work described in this manuscript deals with the search of new members of the a-ketoglutarate and Iron-dependent dioxygenases family (a-KAO) and their applications in organic synthesis. The first part of this work presents the search of new enzymes through a genomic approach based on sequence homology and InterPro motif sharing. Two high-throughput screenings with 79 and 127 candidate enzymes have been performed on 23 and 36 substrates more or less structurally close to known metabolic substrates. 8 new a-KAOs have been discovered. Among these new enzymes, four were studied in more details. After optimization of the enzymatic reaction conditions for each enzyme, scale-up allowed to obtain compounds for isolation and characterization. With these four enzymes, (3S)-3-hydroxy-L-lysine, (4R)-4-hydroxy-L-lysine as its cyclic derivative, (3S)-3-hydroxy-L-ornithine and a derivative of (3S)-3-hydroxy-L-arginine were produced. Two of the new a-KAO were combined in a cascade process to afford the (3R,4R)-3,4-dihydroxy-L-lysine as its cyclic derivative. We proposed a biocatalytic synthesis of mono and hydroxydiamines by coupling one or two a-KAO with a decarboxylase enzyme. (2S)-1,5-diamino-2-pentanol, 1,5-diamino-3-pentanol, (2S)-1,4-diamino-2-butanol and (2S,3S)-1,5-diamino-2,3-pentanediol were obtained with good overall conversions.EVRY-Bib. électronique (912289901) / SudocSudocFranceF

Stereoselective Transaminase-Mediated Synthesis of Serotonin and Melatonin Receptor Agonists

Transaminase enzymes have significant potential for the stereoselective synthesis of drugs or drug precursors. Here, starting from one prochiral β-tetralone, a short and efficient chemoenzymatic synthesis of four agonists of the serotonin/melatonin receptors have been developed. The key step is the stereoselective transamination of the prochiral ketone to produce both enantiomers of 8-methoxy-2-aminotetraline in high yields and enantiomeric excesses. This was followed by either amidation to give the 8-methoxy-2-acetimidotetralines or several facile chemical steps to the 8-hydroxy-2-aminodipropyltetralines

Maternal outcomes and risk factors for COVID-19 severity among pregnant women.

Pregnant women may be at higher risk of severe complications associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may lead to obstetrical complications. We performed a case control study comparing pregnant women with severe coronavirus disease 19 (cases) to pregnant women with a milder form (controls) enrolled in the COVI-Preg international registry cohort between March 24 and July 26, 2020. Risk factors for severity, obstetrical and immediate neonatal outcomes were assessed. A total of 926 pregnant women with a positive test for SARS-CoV-2 were included, among which 92 (9.9%) presented with severe COVID-19 disease. Risk factors for severe maternal outcomes were pulmonary comorbidities [aOR 4.3, 95% CI 1.9-9.5], hypertensive disorders [aOR 2.7, 95% CI 1.0-7.0] and diabetes [aOR2.2, 95% CI 1.1-4.5]. Pregnant women with severe maternal outcomes were at higher risk of caesarean section [70.7% (n = 53/75)], preterm delivery [62.7% (n = 32/51)] and newborns requiring admission to the neonatal intensive care unit [41.3% (n = 31/75)]. In this study, several risk factors for developing severe complications of SARS-CoV-2 infection among pregnant women were identified including pulmonary comorbidities, hypertensive disorders and diabetes. Obstetrical and neonatal outcomes appear to be influenced by the severity of maternal disease

Oxydation biocatalytique de liaison C-H non activée pour la synthèse de dérivés beta-hydroxylamines : application à la synthèse d’acides aminés non protéinogènes

The work described in this manuscript deals with the search of new members of the -ketoglutarate and iron-dependent dioxygenases family (-KAO) and their applications in organic synthesis. The first part of this work presents the search of new enzymes through a genomic approach based on sequence homology and InterPro motif sharing.Two high-throughput screenings with 79 and 127 candidate enzymes have been performed on 23 and 36 substrates more or less structurally close to known metabolic substrates. 8 new -KAOs have been discovered.Among these new enzymes, four were studied in more details. After optimization of the enzymatic reaction conditions for each enzyme, scale-up allowed to obtain compounds for isolation and characterization. With these four enzymes, (3S)-3-hydroxy-L-lysine, (4R)-4-hydroxy-L-lysine as its cyclic derivative, (3S)-3-hydroxy-L-ornithine and a derivative of (3S)-3-hydroxy-L-arginine were produced.Two of the new -KAO were combined in a cascade process to afford the (3R,4R)-3,4-dihydroxy-L-lysine as its cyclic derivative.We proposed a biocatalytic synthesis of mono and hydroxydiamines by coupling one or two -KAO with a decarboxylase enzyme. (2S)-1,5-diamino-2-pentanol, 1,5-diamino-3-pentanol, (2S)-1,4-diamino-2-butanol and (2S,3S)-1,5-diamino-2,3-pentanediol were obtained with good overall conversions.Le travail présenté dans ce manuscrit porte sur la recherche de nouveaux membres de la famille des dioxygénases alpha-cétoglutarate et fer-dépendantes (alpha-KAO) et leur application en synthèse organique. Dans un premier temps, ce travail a consisté à chercher de nouvelles enzymes selon une approche génomique basée sur l’homologie de séquence et le partage d’un motif InterPro.Deux criblages haut débit avec 79 et 127 enzymes candidates ont ensuite été effectués sur des panels constitués respectivement de 23 et 36 substrats, structurellement plus ou moins proches des substrats métaboliques. Six nouvelles -KAO ont ainsi pu être découvertes.Parmi ces six nouvelles alpha-KAO, quatre ont été étudiées en détail. Après optimisation des conditions de réaction pour chaque enzyme, les biotransformations ont été réalisées à une échelle préparative pour caractériser les produits formés. A partir de ces quatre enzymes, la (3S)-3-hydroxy-L-lysine, un dérivé cyclisé de la (4R)-4-hydroxy-L-lysine, (3S)-3-hydroxy-L-ornithine et un dérivé de la (3S)-3-hydroxy-L-arginine ont pu être isolés.Nous avons proposé une synthèse biocatalytique de mono- et dihydroxydiamines en couplant une ou deux alpha-KAO avec une décarboxylase. Les (2S)-1,5-diamino-2-pentanol, 1,5-diamino-3-pentanol, (2S)-1,4-diamino-2-butanol et (2S,3S)-1,5-diamino-2,3-pentanediol ont ainsi été obtenus avec de bons taux de conversion

Biocatalytic oxidation of unactivated C-H bond for the synthesis of beta-hydroxylamine derivatives : application to the synthesis of non proteinogenic amino acids

Le travail présenté dans ce manuscrit porte sur la recherche de nouveaux membres de la famille des dioxygénases α-cétoglutarate et fer dépendantes (α-KAO) et leur application en synthèse organique. Dans un premier, ce travail a consisté à chercher de nouvelles enzymes selon une approche génomique basée sur l’homologie de séquence et le partage d’un motif InterPro. Deux criblages haut débit avec 79 et 127 enzymes candidates ont ensuite été effectués sur des panels constitués respectivement de 23 et 36 substrats, structurellement plus ou moins proches des substrats métaboliques. Huit nouvelles α-KAO ont ainsi pu être découvertes. Parmi ces huit nouvelles α-KAO, quatre ont été étudiées plus en détail. Après optimisation des conditions de réaction pour chaque enzyme, des montées en échelle ont été réalisées pour caractériser les produits formés. A partir de ces quatre enzymes, la (3S)-3-hydroxy-L-lysine, un dérivé cyclisé de la (4R)-4-hydroxy-L-lysine, (3S)-3-hydroxy-L-ornithine et un dérivé de la (3S)-3-hydroxy-L-arginine ont pu être produits. Nous avons proposé une synthèse biocatalytique de mono et dihydroxydiamines en couplant une ou deux α-KAO avec une décarboxylase. Les (2S)-1,5-diamino-2-pentanol, 1,5-diamino-3-pentanol, (2S)-1,4-diamino-2-butanol et (2S,3S)-1,5-diamino-2,3-pentanediol ont ainsi été obtenus avec de bonnes conversions.The work described in this manuscript deals with the search of new members of the α-ketoglutarate and Iron-dependent dioxygenases family (α-KAO) and their applications in organic synthesis. The first part of this work presents the search of new enzymes through a genomic approach based on sequence homology and InterPro motif sharing. Two high-throughput screenings with 79 and 127 candidate enzymes have been performed on 23 and 36 substrates more or less structurally close to known metabolic substrates. 8 new α-KAOs have been discovered. Among these new enzymes, four were studied in more details. After optimization of the enzymatic reaction conditions for each enzyme, scale-up allowed to obtain compounds for isolation and characterization. With these four enzymes, (3S)-3-hydroxy-L-lysine, (4R)-4-hydroxy-L-lysine as its cyclic derivative, (3S)-3-hydroxy-L-ornithine and a derivative of (3S)-3-hydroxy-L-arginine were produced. Two of the new α-KAO were combined in a cascade process to afford the (3R,4R)-3,4-dihydroxy-L-lysine as its cyclic derivative. We proposed a biocatalytic synthesis of mono and hydroxydiamines by coupling one or two α-KAO with a decarboxylase enzyme. (2S)-1,5-diamino-2-pentanol, 1,5-diamino-3-pentanol, (2S)-1,4-diamino-2-butanol and (2S,3S)-1,5-diamino-2,3-pentanediol were obtained with good overall conversions

New enzymes and method for preparing hydroxylated L-lysine or L-ornithine and analogs thereof

The present invention relates to new enzymes displaying L-lysine or L-ornithine hydroxylase activity and their uses for preparing compounds of interest, in particular hydroxy-L-lysine, hydroxy-L-ornithine and hydroxylated diamino alkanes

Clinical metagenomics for the management of hospital- and healthcare-acquired pneumonia

The increasing burden of multidrug-resistant bacteria affects the management of several infections. In order to prescribe adequate antibiotics, clinicians facing severe infections such as hospital-acquired pneumonia (HAP) need to promptly identify the pathogens and know their antibiotic susceptibility profiles (AST), which with conventional microbiology currently requires 24 and 48 h, respectively. Clinical metagenomics, based on whole genome sequencing of clinical samples, could improve the diagnosis of HAP, however, many obstacles remain to be overcome, namely the turn-around time, the quantification of pathogens, the choice of antibiotic resistance determinants (ARDs), the inference of the AST from metagenomic data and the linkage between ARDs and their host. Here, we propose to tackle those issues in a bottom-up, clinically driven approach

New enzymes and method for preparing hydroxylated L-lysine or L-ornithine and analogs thereof

The present invention relates to new enzymes displaying L-lysine or L-ornithine hydroxylase activity and their uses for preparing compounds of interest, in particular hydroxy-L-lysine, hydroxy-L-ornithine and hydroxylated diamino alkanes